Statistically speaking, head and neck cancer per se (excluding melano ma and basal cell carcinoma) does not outwardly seem to pose a serious threat - 27,500/870,000 total cancer cases estimated for 1984 (or 3.2% of all cancers) and 9,350/450,000 total cancer deaths in 1984 (or 2.1 %) for the United States. Yet in clinical practice, by the time that diagnosis is made, more than 60% of oral cancers have already spread to the nearby lymph node system. And while the overall five-year survival rate for localized oral cancer is 67%, this rate decreases drastically to only 25% when the original…mehr
Statistically speaking, head and neck cancer per se (excluding melano ma and basal cell carcinoma) does not outwardly seem to pose a serious threat - 27,500/870,000 total cancer cases estimated for 1984 (or 3.2% of all cancers) and 9,350/450,000 total cancer deaths in 1984 (or 2.1 %) for the United States. Yet in clinical practice, by the time that diagnosis is made, more than 60% of oral cancers have already spread to the nearby lymph node system. And while the overall five-year survival rate for localized oral cancer is 67%, this rate decreases drastically to only 25% when the original cancer has metastasized. Scientific textbooks all too often are merely a compilation of dis crete parts, rather than a correlated, integrated whole. Dr. Hamner and his colleagues have achieved such an integrated, succinct version in The Management of Head and Neck Cancer. The outstanding group of contributors bring to the book a wealth of accumulated knowledge and expertise in their various cancer spe cialty disciplines. They are associated with some of the most distin guished cancer centers in the United States.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Inhaltsangabe
I. General Remarks.- II. Anatomy.- III. Purpose.- References.- 1. Etiology and Epidemiology.- I. Overview.- II. Possible Predisposing Factors.- III. Oral Precancerous Conditions.- IV. Epidemiology.- References.- 2. Detection.- I. Oral Examination.- II. Toluidine Blue as a Screening Detection Method.- III. Oral Cytology as a Screening Detection Method.- References.- 3. Diagnosis.- I. Epidermoid Carcinoma.- II. Carcinoma-in-situ.- III. Basal Cell Carcinoma.- IV. Malignant Melanoma.- V. Odontogenic Tumors.- VI. Fibro-Osseous Lesions.- VII. Salivary Gland Tumors.- VIII. Biopsy.- References.- 4. Pretreatment Evaluation.- I. Medical History and Symptoms.- II. Evaluation of Extent of Disease.- III. Consultations.- IV. Pretreatment Management.- V. Informed Consent.- VI. Non-Standard Treatment.- VII. Rules for Classification.- VIII. TNM Classification.- IX. Postsurgical Treatment Residual Tumor (R).- X. Summary of Stage Groupings.- XI. Common Departures from Sound Management.- References.- 5. Treatment.- I. Surgical Treatment of Head and Neck Cancer. Donald P. Shedd.- References.- II. Radiation Therapy in the Management of Head and Neck Tumors. Luther W. Brady and Lawrence W. Davis.- 1. General Considerations.- 2. The Role of Radiation Therapy in Head and Neck Sites.- 3. Treatment of Neck Nodes.- 4. Late Effects of Radiation Therapy.- 5. Future Approaches.- References.- III. Chemotherapy. James E. Hamner, III.- References.- 6. Follow-Up.- General Considerations.- References.- 7. Rehabilitation.- I. General Principles of Rehabilitation. James E. Hamner, III.- II. Maxillofacial Prosthetics. Joe B. Drane.- References.- 8. Series of Case Examples.- 1. Case No. 1 : Squamous Cell Carcinoma.- 2. Case No. 2: Squamous Cell Carcinoma.- 3. Case No. 3: Cemento-Ossifying Fibroma.- 4. Case No. 4: Osteosarcoma.- 5. Case No. 5: Cherubism.
I. General Remarks.- II. Anatomy.- III. Purpose.- References.- 1. Etiology and Epidemiology.- I. Overview.- II. Possible Predisposing Factors.- III. Oral Precancerous Conditions.- IV. Epidemiology.- References.- 2. Detection.- I. Oral Examination.- II. Toluidine Blue as a Screening Detection Method.- III. Oral Cytology as a Screening Detection Method.- References.- 3. Diagnosis.- I. Epidermoid Carcinoma.- II. Carcinoma-in-situ.- III. Basal Cell Carcinoma.- IV. Malignant Melanoma.- V. Odontogenic Tumors.- VI. Fibro-Osseous Lesions.- VII. Salivary Gland Tumors.- VIII. Biopsy.- References.- 4. Pretreatment Evaluation.- I. Medical History and Symptoms.- II. Evaluation of Extent of Disease.- III. Consultations.- IV. Pretreatment Management.- V. Informed Consent.- VI. Non-Standard Treatment.- VII. Rules for Classification.- VIII. TNM Classification.- IX. Postsurgical Treatment Residual Tumor (R).- X. Summary of Stage Groupings.- XI. Common Departures from Sound Management.- References.- 5. Treatment.- I. Surgical Treatment of Head and Neck Cancer. Donald P. Shedd.- References.- II. Radiation Therapy in the Management of Head and Neck Tumors. Luther W. Brady and Lawrence W. Davis.- 1. General Considerations.- 2. The Role of Radiation Therapy in Head and Neck Sites.- 3. Treatment of Neck Nodes.- 4. Late Effects of Radiation Therapy.- 5. Future Approaches.- References.- III. Chemotherapy. James E. Hamner, III.- References.- 6. Follow-Up.- General Considerations.- References.- 7. Rehabilitation.- I. General Principles of Rehabilitation. James E. Hamner, III.- II. Maxillofacial Prosthetics. Joe B. Drane.- References.- 8. Series of Case Examples.- 1. Case No. 1 : Squamous Cell Carcinoma.- 2. Case No. 2: Squamous Cell Carcinoma.- 3. Case No. 3: Cemento-Ossifying Fibroma.- 4. Case No. 4: Osteosarcoma.- 5. Case No. 5: Cherubism.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826